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Background: Cell panning of phage-displayed antibody library is a powerful tool for the development of
therapeutic and imaging agents since disease-related cell surface proteins in native complex conformation can be
directly targeted. Here, we employed a strategy taking advantage of an integrated vector system which allows
rapid conversion of scFv-displaying phage into scFv-Fc format for efficient cell-based scFv library selection on a
tetraspanin protein, CD9.
Results: A mouse scFv library constructed by using a phagemid vector, pDR-D1 was subjected to cell panning
against stable CD9 transfectant, and the scFv repertoire from the enriched phage pool was directly transferred to a
mammalian cassette vector, pDR-OriP-Fc1. The resulting constructs enabled transient expression of enough
amounts of scFv-Fcs in HEK293E cells, and flow cytometric screening of binders for CD9 transfectant could be
performed simply by using the culture supernatants. All three clones selected from the screening showed correct
CD9-specificity. They could immunoprecipitate CD9 molecules out of the transfectant cell lysate and correctly stain
endogenous CD9 expression on cancer cell membrane. Furthermore, competition assay with a known anti-CD9
monoclonal antibody (mAb) suggested that the binding epitopes of some of them overlap with that of the mAb
which resides within the large extracellular loop of CD9.
Conclusions: This study demonstrates that scFv-Fc from mammalian transient expression can be chosen as a
reliable format for rapid screening and validation in cell-based scFv library selection, and the strategy described
here will be applicable to efficient discovery of antibodies to diverse cell-surface targets.
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Phage display of antibody fragments is now well estab-
lished technology and has enabled the construction and
selection of a large size of antibody library in vitro [1,2].
Selection of phage library includes panning procedure
for enrichment of target-specific phage and subsequent
screening procedure for individual phage clones. For the
evaluation of candidate clones, antibody fragments in
the form of scFv or Fab can usually be expressed in
enough quantity by bacterial cells. Though bacterial* Correspondence: sjick@kribb.re.kr
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reproduction in any medium, provided the orexpression is sufficient for most purposes, some sensitive
biological assays as well as in vivo validation prefer
mammalian expression of antibody. Several reports has
thus described construction of cassette-type vectors for
rapid conversion of phage-displayed antibody fragments
into whole IgG or scFv-Fc format to accelerate the valid-
ation process that is done under in vivo conditions
closely mimicking those expected to occur with thera-
peutics and imaging agents [3-5].
For the development of therapeutic or imaging agents,
cell surface antigens are attractive targets. Cell panning
procedure that allows selection of phage-displayed anti-
body library directly on intact cells has been employed
to target the antigens in their native conformation at thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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limitations of the conventional selection procedure using
purified recombinant antigens immobilized on artificial
surfaces. In fact, some cell surface proteins cannot be
expressed in recombinant forms that retain their native
conformation, and antibodies selected using the recom-
binant proteins may not bind to original proteins on cell
surface. Furthermore, the procedure gives chances to
target novel epitope space created by disease-related
overexpression or modification of cell surface proteins.
CD9 is a cell surface glycoprotein that belongs to the
tetraspanin family containing four transmembrane
domains and two extracellular loops [11]. Its expression
has been recently reported to be related to some
cancers and proposed to be a potential therapeutic target
[12-15]. In this study, we aimed to generate antibodies
recognizing CD9 on the cell surface in its native conform-
ation. For this purpose, stable transfectant expressing
CD9 has been constructed and used for entire process of
panning of phage library and subsequent screening and
characterization of individual antibody clones.
To facilitate the whole cell-based screening and
characterization, we took advantage of an integrated vec-
tor system which allows direct conversion of scFv phage
into scFv-Fc format [16]. After cell panning on the CD
transfectant, the enriched scFv repertoire in phagemid
vector, pDR-D1 was transferred into mammalian cassette--- atg aaa tac cta ttg cct a
M   K   Y   L   L P   
pelB
SfiI
gcg gcc cag ccg gcc atg gcc -
A   A Q   P   A   M   A
aag ctg atc tct gag gaa gac c
K   L   I   S   E   E D   
Myc tag
gga --- --- gag tct taa gct a
G   ~   ~   E   S stop     
gene III (230-406)
cat cat cac cat cac taa ---







Figure 1 Schematic representation (A) and sequences (B) of major co
vector is derived from pComb3H with some modifications which result in
sequences and gene III sequences removable by NotI-NotI between two ta
control of the LacZ promoter (pLacZ).vector, pDR-OriP-Fc1 simply by cut and paste restriction
fragment cloning. Enough amount of scFv-Fc could be
obtained from transient expression by using the result-
ing constructs in HEK293E cells, which enabled rapid
identification and characterization of specific binders to
cell surface CD9 using flow cytometry, immunoprecipi-
tation and immunofluorescence confocal microscopy.
The results demonstrate feasibility of the strategy using
the integrated vector system that allows use of scFv-Fc
as a reliable format for rapid cell-based antibody screen-
ing and validation.
Results
Design features of the integrated vector system
Here we used two vectors, pDR-D1 (Figure 1A) for
phage display of scFv and pDR-OriP-Fc1 (Figure 2A) for
mammalian expression of scFv-Fc. They are designed to
allow rapid shuttling of scFv inserts, and the sequences
of scFv inserts in pDR-D1 can be directly transferred
into pDR-OriP-Fc1 simply by cut and paste restriction
fragment cloning without PCR-amplification step.
Detailed sequences show design features of the inte-
grated vector system (Figure 1B and Figure 2B).
pDR-D1 includes pelB signal sequences for periplasmic
expression in E. coli and two SfiI restriction sites (5’-
GGCCNNNNNGGCC-3’) for the cloning of scFv
(Figure 1B). The two SfiI sites have different NNNNNcg gca gcc gct gga ttg tta tta ctc
T   A   A A G   L   L L L
signal peptide
SfiI
-- --- ggc ccg gga ggc ctc gag cag
~   ~ E   Q
scFv
NotI
tg gcg gcc gct caa gcc gga cag gag
L E
NotI
gc taa tta att taa gcg gcc gca cat




mponents of phagemid vector, pDR-D1 for phage display. The
SfiI-SfiI cassette sequences for scFv cloning followed by pelB signal
gs, Myc and hexahistidine (His6) tags. The expression unit is under the
--- atg gag aca gac aca atc ctg cta tgg gtg ttg tta tta ctc
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scFv human 
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Figure 2 Schematic representation (A) and sequences (B) of major components of mammalian cassette vector, pDR-OriP-Fc1 for
transient expression of scFv-Fc. The vector is derived from pcDNA3.1 with some modifications which result in the same SfiI-SfiI cassette
sequences as pDR-D1 for scFv cloning followed by hybrid signal sequences composed of mouse kappa leader (Lmκ) and pelB signal sequences.
Human Fcγ1 (hFc) sequences and hinge region are followed by the cloning site to allow in-frame fusion of scFv and hFc. The scFv-Fc expression
unit is under the control of the human cytomegalovirus promoter (phCMV). oriP sequences are also included to mediate episomal amplification
and maintenance of the transfected episomal DNA in 293E cells.
Table 1 Cell panning of scFv library on HEK293-CD9 in
three rounds
1st round 2nd round 3rd round
Phage input (cfua) 1 × 1013 3.16 × 1011 2.08 × 1011
Phage output (cfu) 1.48 × 105 7.40 × 104 6.56 × 105
Recovery rateb 1.48 × 10-8 2.34 × 10-7 3.15 × 10-6
a cfu: colony forming unit.
b Recovery rate: output/input ratio used to determine the phage recovery rate
of each round.
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allowing a directional cloning [17]. The sequences for
myc tag are followed by SfiI sites for the detection of
scFv expression. Also, pDR-D1 includes gene III
sequences (aa 230–406) for the display of scFv. The gene
III sequences are designed to be removable by two NotI
restriction sites for soluble expression of scFv. The
sequences for His6 tag are designed to be attached to
those for myc tag after removing gene III sequences for
the detection and purification of scFv.
For in-frame transfer of scFv from pDR-D1, pDR-
OriP-Fc1 was designed to have hybrid signal sequences
(Figure 2B). The initial half sequences (METDTILLWV)
are derived from mouse kappa leader sequences, and the
last half sequences (LLLLAAQPAMA) from pelB leader
sequences. The derived hybrid signal peptide was proved
to be functional in mammalian cells before [5,16]. The
resulting construct has the same SfiI sites as those in
pDR-D1 and, even unknown sequences derived from
pDR-D1 based library can be directly cloned into pDR-
OriP-Fc1. The cloned scFv is designed to be fused to
human Fcγ1 through the hinge region which results in
Fc-fused dimer forms when expressed in mammalian
cells. pDR-OriP-Fc1 also includes OriP sequences which
allows enhanced and prolonged protein expression in
293E cells containing EBNA-1 [18].
Selection of antibodies recognizing CD9 on cell surface
A naïve mouse scFv library with an estimated diversity of
2 × 109 was prepared by cloning antibody repertoire
derived from mouse splenocytes into pDR-D1 as described
in Materials and Methods. Integrity of the library wasconfirmed by DNA sequencing of scFv inserts from ran-
domly picked library clones. Library phages were rescued
using VCSM13 helper phage and confirmed for scFv dis-
play on phage surface using western blot (Data not
shown).
To select antibodies against native form of CD9 on cell
surface, cell panning was performed using a stable CD9
transfectant, HEK293-CD9. The library phages were pre-
cleared by subtraction panning with parental HEK293 to
deplete non-specific binding phages. The pre-cleared
phages were incubated with HEK293-CD9 cells, and
bound phages were recovered and amplified for next
round of panning. Three rounds of panning were per-
formed, and enrichment of HEK293-CD9 binders was
monitored by titering the number of phage recovered
after panning. Phage recovery rate (output/input ratio)
after the 3rd round was about 200-fold higher than that
after the 1st round (Table 1), which indicated successful
enrichment of HEK293-CD9 binders.
For reliable screening of individual antibody clones,
scFv-Fc format was chosen instead of phage format. The
use of mammalian cassette vector, pDR-OriP-Fc1 allowed
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toire in the phage pool enriched after 3rd round of pan-
ning was directly transferred to mammalian cassette
vector for scFv-Fc expression by cloning scFv inserts
extracted from phagemid DNA prepared after 3rd round
of panning into pDR-Orip-Fc1. Twenty clones were ran-
domly selected and subjected to DNA sequencing. Ten
unique scFv sequences were identified, and the vectors
harboring the scFv sequences were transfected into 293E
cells for transient expression. The culture supernatant
was confirmed for scFv-Fc expression by detection of
55 kDa bands in western blot analysis (Figure 3A) and
directly used for flow cytometric screening of scFv-Fc for
its binding to HEK293-CD9 (Figure 3B). HA6 specific for
HAV (Hepatitis A Virus) was used as negative control,
and MM2/57, anti-CD9 mAb was used as positive con-
trol. Three clones (E3, E8 and F7) were strongly positive
for binding to HEK293-CD9 and could differentiate CD9
overexpression like MM2/57. However, the other clones
such as E1 were not positive and could not differentiate
CD9 overexpression (Figure 3B).
Characterization of scFv-Fcs
For further characterization, the selected scFv-Fcs were
purified from the culture supernatants by using protein
G column. From 30 ml of serum-free culture super-
natant, 100 ~ 200 μg of purified scFv-Fc could be
obtained, and its purity was confirmed by a single
55 kDa band on a 12% SDS-PAGE in reducing condition
(Data not shown).
First, their binding specificity for CD9 was tested by
using immunoprecipitation and immunoblotting
(Figure 4A). As anticipated, E3, E8 and F7 could pull
down about 25 kDa of CD9 molecules from cell lysate of
HEK293-CD9, which was recognized by immunobloting
with MM2/57. This result confirmed CD9-specificity of
the selected antibodies indicating success of the cell-
based selection.
Next, we examined whether the selected scFv-Fcs
could recognize endogenous CD9 expression on human
cancer cells using flow cytometry and immunofluores-
cence confocal microscopy. Two cancer cell lines were
used for comparison. MKN-28, a human gastric cancer
cell line is known to overexpress CD9, whereas HepG2,
hepatocarcinoma cell line not to express CD9 [19]. As
expected, flow cytometric analysis revealed strong bind-
ing of all three scFv-Fcs to MKN-28 when compared
with their binding to HepG2 (Figure 4B). This strong
binding could be confirmed by localizing CD9 staining
on MKN-28 with the scFv-Fcs using confocal micros-
copy (Figure 4C). CD9 staining by the scFv-Fcs and
MM2/57 was mainly observed on the cell membrane of
MKN-28 but not on that of HepG2 whereas staining by
HA6 was barely seen for both cell lines. Hence, all threescFv-Fvs could specifically recognize endogenous CD9
expression on the cell membrane of MKN-28.
Finally, competition binding experiments using flow
cytometry were carried out to test whether the binding
epitopes of the selected scFv-Fcs would overlap with that
of MM2/57. MM2/57 is known to recognize large extra-
cellular loop (ECL2) of CD9 molecule [20]. As shown in
Figure 5, addition of E3 or F7 as competitor inhibited the
binding of MM2/57 to MKN-28 cells while addition of E8
did not affect the binding at all like HA6. The data suggest
that E3 and F7 share their epitopes with MM2/57 that
may be present at ECL2 domain of CD9 molecule.
Discussion
In this study, we demonstrated an efficient selection
of antibodies recognizing cell surface CD9 from phage-
displayed scFv library by taking advantage of an inte-
grated vector system. A mouse scFv library was
constructed using phagemid vector, pDR-D1, and after
cell panning against CD9 transfectant, the enriched scFv
repertoire was directly transferred to mammalian cas-
sette vector, pDR-OriP-Fc1. Since the resulting cassette
vector constructs enabled transient expression of enough
amounts of scFv-Fcs in HEK293E cells, flow cytometric
screening of binders for CD9 transfectant could be
performed simply by using the culture supernatants
(Figure 3). Compared with phage, scFv-Fc format could
be preferred choice for the reliable screening of individ-
ual clones especially after cell panning procedure. It is
known that cell panning procedure usually suffers from
high background binding of non-specific phages [21,22].
Likewise, phage screening directly on cell can cause
selection of non-specific binders. By adapting scFv-Fc
format instead of phage, we wished to discriminate CD9-
specific binders from non-specific binders at the screen-
ing step. In fact, all three clones selected from FACS
screening were found to be CD9-specific (Figure 4A).
Their specificity could be confirmed by recognition of
endogenous CD9 expression on cancer cells. It appeared
that their binding results were slightly positive even on
CD9 negative HepG2 cells by flow cytometry when com-
pared with that of anti-CD9 mAb, MM2/57 (Figure 4B).
This might be attributed to their lower specificity. How-
ever, all three could correctly localize membrane-bound
CD9, and the results were comparable to that of MM2/
57 (Figure 4C). Most anti-tetraspanin mAbs including
MM2/57 is known to recognize epitopes within ECL2
regions [20]. Our competition data indicated that two of
selected scFv-Fcs (E3 and F7) might recognize the
immunodominant epitope regions at the ECL2 domain
of CD9 which overlap with that of MM2/57 (Figure 5).
But the other one, E8 showed different epitope specifi-
city. CD9 like the other tetrapanins can assemble into








Figure 3 Screening of scFv-Fcs binding to cell surface CD9. (A) Western blot analysis of scFv-Fc expression. HRP-conjugated rabbit
anti-human IgG (Fc-specific) antibody was used to detect scFv-Fc in culture supernatant. (B) Flow cytometric analysis of scFv-Fc binding. Culture
supernatants containing scFv-Fcs were analyzed for the ability to bind HEK293 (open histogram) and HEK293-CD9 (shaded histogram) by flow
cytometry. HA6 represents an scFv-Fc recognizing HAV used as a negative control, and MM2/57 represents an anti-CD9 mAb used as a positive
control. The binding of scFv-Fc and MM2/57 was detected by FITC-conjugated rabbit anti-human IgG (Fc-specific) antibody and FITC-conjugated
goat anti-mouse IgG antibody, respectively.















Figure 4 Characterization of the selected scFv-Fcs. (A) Immunoprecipitation of CD9 molecule by the scFv-Fcs. Cell lysate of HEK293-CD9 was
immunoprecipiated by using each antibody indicated on the top of the lane. The immunoprecipitates were resolved by 14% SDS-PAGE and
analyzed by immunoblotting with MM2/57. (B) Flow cytometric analysis of binding of the scFv-Fcs to endogenous CD9 on human cancer cells.
MKN-28 and HepG2 cells were stained with the indicated antibody and the corresponding FITC-conjugated secondary antibody as described in
Figure 3. The open histograms in the left represent the data acquired by the FITC-conjugated secondary antibody only. (C) Immunolocalization of
endogenous CD9 on cancer cells by the scFv-Fcs. MKN-28 and HepG2 cells grown on coverslips were stained with the indicated antibody and
the corresponding FITC-conjugated secondary antibody. The cellular nucleus was dyed blue fluorescence with DAPI staining. The stained cells
were observed using a confocal microscope (400×).





Figure 5 Flow cytometric analysis of competitive binding of the scFv-Fcs with anti-CD9 mAb, MM2/57. MM2/57 antibody was incubated
with MKN-28 cells in the presence (closed histogram) and absence (open histogram) of the indicated scFv-Fcs. Bound MM2/57 was detected by
FITC-conjugated goat anti-mouse IgG antibody. Histograms drawn in dotted line in the far left represent the data acquired by the
FITC-conjugated secondary antibody only.
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tensive screening can give more chances to select rare
antibodies recognizing novel epitopes created by such
dynamic molecular changes.
Direct selection of phage-displayed antibody library on
intact cells is inevitable for some cell surface proteins
with complex structural features which make them diffi-
cult to be recombinantly expressed in fully native forms.
Selection on such recombinant proteins could result in
antibodies that failed to correctly recognize their original
conformation on cell surface as exemplified previously
[10]. Cell-based selection has another advantage over re-
combinant protein-based selection in that it can give a
chance to generate antibodies with novel epitope specifi-
city that can differentiate disease-related cell surface sig-
natures. According to studies on epitope structure of
tumor-associated epidermal growth factor receptor
(EGFR), EGFR overexpression on cancer cells exposes
neo-epitope that is not found in EGFR on normal tissues
[26,27]. Besides overexpression, other factors such as
aberrant posttranslational modification and multi-
molecular clustering can affect conformation of cellsurface proteins, which may result in exposure of novel
epitope space.
Conclusions
Cell surface expression of disease-related proteins such
as tumor-associated antigens is promising target of anti-
body development for therapeutic and imaging applica-
tions. Cell-based selection using phage-displayed
antibody library is a powerful tool for such purpose but
needs reliable evaluation of specific binders for efficient
selection. As demonstrated in this report, rapid conver-
sion of the scFv phages enriched after cell panning into
scFv-Fc format by taking advantage of a mammalian cas-
sette vector will allow efficient development of anti-
bodies for diverse cell surface proteins with complex
conformation by accelerating cell-based evaluation steps.
Methods
Integrated vector system for antibody display and
selection
A phagemid vector, pDR-D1 (Figure 1) was used for
cloning and display of antibody repertoire as described
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sequences, SfiI-SfiI restriction enzyme sites for scFv
cloning and sequences for myc tag between lac Z pro-
moter and gene III. Also, hexahistidine (His6) tag is
designed to be linked to myc tag after removing gene III
using NotI-NotI restriction enzyme sites for soluble ex-
pression and purification of scFv in E.coli.
For rapid conversion of phage displayed scFv into Fc-
fusion form, a mammalian expression vector, pDR-OriP-
Fc1 (Figure 2) was used as described previously [16].
Briefly, the vector was constructed by reengineering
pcDNA3.1 (Invitrogen, Carlsbad, CA) to contain human
Fcγ1 sequences and hinge region followed by scFv clon-
ing sites as well as OriP sequences. The hybrid signal
peptide sequences consisting of leader sequences of
kappa chain of mouse IgG and pelB were also included
upstream of SfiI-SfiI sites for direct cloning of scFv
sequences from pDR-D1.CD9 expression constructs and cell lines
Human CD9 cDNA was cloned into expression vector,
pcDNA3.1/zeo(+) (Invitrogen). Human embryonic
kidney-293 (HEK293) cells were transfected with the
plasmid using Lipofectamine (Invitrogen). Stable trans-
fectants were selected using 400 μg/ml of zeocine (Invi-
trogen) in Dubecco’s modified Eagle’s Medium (DMEM,
Invitrogen) supplemented with 10% fetal bovine serum
(FBS, Invitrogen). A stable transfectant, HEK293-CD9
was used for library panning and selection. Two human
cancer cell lines were used for the characterization of
CD9-specificity of selected antibodies. Human gastric
cancer cell line, MKN-28 was maintained in RPMI-1640
medium (Invitrogen) supplemented with 10% FBS, and
human hepatocellular carcinoma cell line, HepG2 in
DMEM medium with 10% FBS.Library construction and panning
A naïve mouse scFv library was constructed from BALB/
c mice (Daehan Biolink Co., Umsong, Korea) by cloning
the mouse antibody repertoire into pDR-D1 as described
previously [16]. Briefly, a mouse splenocyte suspension
was prepared and subjected to total RNA extraction,
cDNA synthesis, and PCR amplification of heavy and
kappa chain variable regions (VH and VK). The ampli-
fied VH and VL containing BbsI site were linked by
ligation, and the combined scFv repertoire was subjected
to extension PCR with primers containing SfiI site. The
amplified scFv inserts and pDR-D1 were digested with
SfiI, and, after ligation, the final constructs were electro-
porated into E. coli ER2738 cells. Bacteriophages display-
ing the scFv repertoire were rescued by the infection of
the transformed cells with VCSM13 helper phage (Stra-
tagene, La Jolla, CA).The rescued phage library was used for cell panning
which was performed according to conventional pro-
tocols [8,9] with slight modification. The library was
pre-incubated with HEK293 cells in PBA (1% bovine
serum albumin/0.02% sodium azide/PBS) at 4°C for
1 h. The subtracted phages were recovered by centri-
fugation and then incubated with HEK293-CD9 cells
at 4°C for 1 h. The cells were washed with ice-cold
PBA four times, and the bound phages on the cell
surface were amplified by infecting ER2738 cells fol-
lowed by helper phage super-infection. The amplified
phages were then subjected to another round of
panning.
Expression and purification of scFv-Fc
After third round of panning, phagemid DNA was
extracted from the ER2738 cells infected with the
enriched phages. The scFv inserts were cut out of the
phagemid by SfiI-digestion and directly cloned into
pDR-OriP-Fc1. Twenty clones were randomly selected
and subjected DNA sequencing. The nucleotide
sequences determined were submitted to IMGT/V-
QUEST (http://imgt.cines.fr/vquest) for sequence ana-
lysis. As a negative control, scFv against Hepatitis A
virus was constructed from VH and VK sequences of
HA6 [28] and also cloned into pDR-OriP-Fc1.
The resulting scFv-Fc expression plasmid was intro-
duced into 293E cells (CRL-10852, ATCC) using Lipo-
fectamine. The transfected cells were grown in DMEM
containing 10% FBS and subsequently, the media were
changed to serum-free media, and the culture super-
natant was harvested every 3 day. The culture super-
natant was confirmed for scFv-Fc expression by western
blot and used for flow cytometric screening of specific
binders. For purification of scFv-Fc, the culture super-
natant was subjected to affinity chromatography on a
Protein G-agarose column (Merck Millipore, Darmstadt,
Germany) as described previously [28].
Flow cytometry
For the screening of scFv-Fcs binding to HEK293-CD9,
flow cytometric analysis was performed using the culture
supernatant. HEK293 and HEK293-CD9 cells were
grown to 70–80% confluence and harvested by trypsini-
zation. About 1 × 106 cells were washed with ice-cold
PBS and then blocked with PBA for 10 min at 4 °C. 100
μL of the culture supernatant was added to the cells and
incubated for 1–2 h at 4 °C. After washing with PBA,
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-
human IgG (Fc-fragment specific, Pierce, Rockford, IL)
was added to the cells for the detection of bound scFv-
Fcs. After 30 min incubation, the cells were washed
twice with PBA and resuspended in PBS containing pro-
podium iodide (PI). PI negative cells were gated and
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Bioscience, San Jose, CA) and Cell Quest software (BD
Bioscience).
Staining of cancer cell lines with purified scFc-Fv was
also performed on MKN-28 and HepG2 cells. Cells
grown to 70–80% confluence were harvested and stained
as described above. For comparison, a monoclonal anti-
body (mAb) against CD9, clone MM2/57 (Merck milli-
pore) was used as positive control, and its binding to the
cells was detected using FITC-conjugated goat anti-
mouse IgG (Pierce).
Immunoprecipitation and immunoblotting
The binding specificity of scFv-Fc to CD9 was tested
by immunoprecipitation and immunoblotting. HEK293-
CD9 cells grown to 70-80% confluence were lysed at
4 °C in a lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 5 mM sodium fluoride, 1 mM
ethylenediaminetetraaceticacid (EDTA), 1 mM ß-glycer-
ophosphate, Xpert Protease Inhibitor Cocktail solution
(GenDEPOT, Barker, Tx)). After removing insoluble frac-
tion by centrifugation, the cell lysate was depleted with
protein G-agarose for 30 min at 4 °C. The depleted cell
lysate was then incubated with scFv-Fc or MM2/57 for
3 h at 4 °C. The immune complexes were captured on
protein G-agarose and washed three times with the lysis
buffer. After treatment with non-reducing protein load-
ing buffer, the immunoprecipitates were resolved by 14%
SDS-PAGE and transferred to PVDF membranes. The
membrane was blocked with 4% skim milk in PBS and
incubated with MM2/57. After washing with 0.01%
Tween20 in PBS, the bound antibody was detected with
horseradish peroxidase (HRP)-conjugated anti-mouse
IgG (Fc specific, Jackson ImmunoResearch Laboratories,
West Grove, PA).
Immunofluorescence confocal microscopy
Confocal laser scanning microscopy was performed on
MKN-28 and HepG2 cells to visualize cell surface bind-
ing of scFv-Fcs. The glass coverslips were coated with
0.1% gelatin overnight, washed once with PBS and dried
overnight. The cells were seeded on the gelatin-coated
coverslips at 2 × 105 cells/slip and allowed to adhere for
48 h at 37 °C. After washing with ice cold PBS twice, the
cells were incubated with scFv-Fc or MM2/57 for 2 h at
room temperature. Unbound antibody was removed by
washing with ice-cold PBS, and the cells were fixed with
4% formalin solution at room temperature for 15 min.
After three times washing with ice-cold PBS, bound
scFv-Fc and MM2/57 were stained with FITC-
conjugated rabbit anti-human IgG and FITC-conjugated
goat anti-mouse IgG1, respectively. Finally, coverslips
were mounted by applying Vectashield solution (Vectorlaboratories, Burlingame, CA) and, the stained cells were
observed with a confocal laser scanning microscope (Carl
zeiss 510 META, Carl Zeiss, Oberkochen, Germany).
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